Calciphylaxis Treatment Market Analysis & Forecast: 2026-2033

Calciphylaxis Treatment Market Size and Forecast: 2026-2033

The Calciphylaxis Treatment Market is anticipated to grow at a CAGR of 8.6% with USD 18.6 Bn share in 2026 and is expected to reach USD 23.7 Bn in 2033. Rising cases of chronic kidney disease and end-stage renal disease drive the calciphylaxis treatment market. In 2023, an estimated 788 million people were living with chronic kidney disease (CKD), with an age-adjusted prevalence of 14.2% among adults aged 20 years and older worldwide. Healthcare providers are increasing awareness of rare vascular disorders, while hospitals and clinics are adopting advanced wound care therapies.

Key Takeaways

• Hyperbaric Oxygen Therapy hold the largest market share of 52.2% in 2026 owing to its rising prevalence of chronic kidney disease (CKD) and end-stage renal disease (ESRD).
• Hospitals and Clinics are expected to account for the largest market share of 43.7% in 2026, supported by the high hospitalization rate among calciphylaxis patients. Studies indicate that calciphylaxis is associated with a one-year mortality rate ranging from 45% to 80%, often necessitating intensive inpatient care, wound management, and multidisciplinary treatment.
• North America is anticipated to dominate the market with a 39.2% share in 2026, owing to strong adoption of advanced treatment modalities and a high prevalence of kidney disease. In the United States, approximately 37 million adults are estimated to have CKD, while ESRD affects more than 800,000 individuals, supporting sustained demand for calciphylaxis treatment options.

Current Events and Their Impact on the Calciphylaxis Treatment Market

Uncover macros and micros vetted on 75+ parameters: Get instant access to report

Segmental Insights

To learn more about this report, Request Free Sample

Why is Hyperbaric Oxygen Therapy Acquiring the Largest Market Share?

Hyperbaric Oxygen Therapy hold the largest market share of 52.2% in 2026. Healthcare providers are increasingly adopting Hyperbaric Oxygen Therapy (HBOT) in the calciphylaxis treatment market because it promotes wound healing, improves tissue oxygenation, lowers infection risk, and helps manage pain associated with severe skin lesions. The rising prevalence of chronic kidney disease and end-stage renal disease is driving demand for advanced supportive treatments. More than 800,000 individuals in the United States were living with end-stage renal disease (ESRD), with approximately 68% receiving dialysis and 32% living with a functioning kidney transplant. Hospitals and specialty clinics are expanding multidisciplinary treatment approaches and investing in hyperbaric treatment facilities. In addition, growing awareness among healthcare professionals and rising clinical interest in adjunctive therapies for complex calciphylaxis cases continue to support HBOT adoption. In response to this, in March 2026, Medical Education and Skill Development Minister Dr Sharanprakash Patil inaugurated the Hyperbaric Oxygen Therapy (HBOT) service at the Karnataka Institute of Endocrinology & Research Institute (KIER) in Indiranagar.

Which End User segment dominates the market?

To learn more about this report, Request Free Sample

Hospital and Clinics expected to hold largest market share of 43.7% in 2026 owing to the improved diagnostic capabilities in tertiary care centers. Hospitals and clinics are driving growth in the calciphylaxis treatment market by providing specialized and multidisciplinary care for patients with severe complications. Healthcare providers use these settings to deliver advanced wound management, dialysis support, surgical interventions, infection control, and adjunctive therapies such as Hyperbaric Oxygen Therapy and sodium thiosulfate treatment. The increasing prevalence of chronic kidney disease (CKD) and end-stage renal disease (ESRD) is raising hospital admissions and treatment demand. According to the U.S. Centers for Disease Control and Prevention (CDC), approximately 15% of U.S. adults—around 35.5 million people—have CKD, while patients with ESRD experience hospitalization rates several times higher than the general population due to complications requiring intensive medical care. In response, in December 2025, Holland Hospital has launched a newly renovated hyperbaric oxygen therapy (HBOT) suite, allowing Lakeshore patients to receive treatment locally instead of traveling to Grand Rapids for time-intensive sessions lasting several weeks.

Calciphylaxis Treatment Market Trends

• Increasing adoption of multidisciplinary treatment approaches combining sodium thiosulfate therapy, wound care, dialysis optimization, pain management, and Hyperbaric Oxygen Therapy (HBOT) is improving patient outcomes and survival rates. This trend is gaining importance as calciphylaxis is associated with a one-year mortality rate of approximately 45%–80%, making comprehensive treatment strategies critical for patient management.
• Growing use of advanced wound-care technologies, including negative-pressure wound therapy, biologic dressings, and infection-control solutions, is enhancing healing in severe calciphylaxis lesions. Clinical studies indicate that ulceration occurs in more than 80% of calciphylaxis cases, significantly increasing the risk of infection and sepsis, thereby driving demand for advanced wound-care products.
• Supportive healthcare reimbursement policies for dialysis care, wound management, hospitalization, and adjunctive therapies are improving patient access to specialized calciphylaxis treatment services in developed healthcare markets. In the United States, Medicare spends over USD 50 billion annually on ESRD-related care, supporting access to dialysis and associated therapies commonly used in calciphylaxis treatment.

Regional Insights

To learn more about this report, Request Free Sample

North America dominates owing to high healthcare expenditure

North America is expected to acquire the dominant share of 39.2% in 2026. The region leads growth in the calciphylaxis treatment market due to its substantial burden of kidney disease and strong healthcare infrastructure. According to the CDC, approximately 35.5 million U.S. adults (about 14% of the population) have chronic kidney disease (CKD), while the United States records more than 130,000 new cases of end-stage renal disease (ESRD) annually. The region also benefits from a large dialysis network, with over 7,500 dialysis facilities operating across the U.S., supporting the management of high-risk patients. Healthcare providers actively utilize advanced treatment modalities such as sodium thiosulfate, Hyperbaric Oxygen Therapy (HBOT), and surgical interventions. Additionally, the United States spends over USD 4.5 trillion annually on healthcare, facilitating access to specialized wound-care services and advanced therapies. Growing disease awareness, favorable reimbursement for dialysis and hospital care, and ongoing clinical research into novel calciphylaxis therapies continue to support market expansion across North America.

Asia Pacific Calciphylaxis Treatment Market Trends

Rising cases of chronic kidney disease (CKD) and end-stage renal disease (ESRD) requiring dialysis are driving the Asia Pacific calciphylaxis treatment market by increasing the at-risk patient pool. The region accounts for a significant share of the global CKD burden, with an estimated 434 million people affected across Asia in 2023, representing the largest regional concentration worldwide. In addition, countries such as China and India together contribute a major proportion of global diabetes cases, with over 230 million adults living with diabetes in the Asia Pacific region, further elevating vascular calcification risk.

United States Calciphylaxis Treatment Market Trends

In the United States, several factors drive the calciphylaxis treatment market. Rising cases of end-stage renal disease (ESRD) and dialysis dependence increase the at-risk patient pool, supporting higher treatment demand. The U.S. has more than 800,000 people living with ESRD, with around two-thirds receiving dialysis, making them highly vulnerable to calciphylaxis. Clinicians are also identifying cases earlier due to improved awareness and diagnostic support, which is critical given that calciphylaxis carries a one-year mortality rate of approximately 4%.

China Calciphylaxis Treatment Market Trends

Rising cases of end-stage renal disease and chronic kidney disease in China drive demand for calciphylaxis treatment by increasing the number of at-risk patients. Expanding dialysis centers and growing clinical awareness improve early detection and encourage timely treatment. Strengthening healthcare infrastructure and wider availability of therapies such as sodium thiosulfate support patient care. Active clinical research and government initiatives for rare disease management further boost the market, while an aging population with diabetes-related complications increases overall treatment needs.

Who are the Major Companies in Calciphylaxis Treatment Industry

Some of the major key players in Calciphylaxis Treatment are 3M, Amgen Inc., BSN Medical, ConvaTec Inc., Medtronic Plc., Smith & Nephew Plc., and Laboratoris Sanifit S.L.

Key News

• In January 2025, HCG Manavata Cancer Centre (HCG MCC) launched its Hyperbaric Oxygen Therapy (HBOT) department to speed up healing and improve patient recovery. The centre equipped the new HBOT facility to treat up to four patients at once, upgrading from traditional monoplace chambers.

Market Report Scope

Analyst Opinion

• Calciphylaxis treatment demand is not being shaped by discretionary clinical expansion but by the harsh reality of renal disease burden. Around 10% of the global population lives with chronic kidney disease, and among dialysis patients, calciphylaxis, though rare remains one of the most fatal dermatological-vascular complications, with reported mortality exceeding 50% within the first year of diagnosis. This makes treatment adoption less of a choice and more of an emergency response in nephrology units.
• Clinically, sodium thiosulfate has become a frequently used off-label intervention in hospital settings, particularly across dialysis-dependent populations, despite the absence of universally standardized dosing protocols. Case series from tertiary care centers consistently report partial lesion resolution in a significant proportion of treated patients, reinforcing its practical reliance in real-world nephrology practice rather than controlled guideline-driven pathways.
• The market is also being pulled by late and difficult diagnosis patterns. Studies suggest that patients often experience weeks of misdiagnosis due to overlapping symptoms with cellulitis and ischemic ulcers, which delays intervention and worsens outcomes. This diagnostic gap forces clinicians to rely on empiric treatment approaches in advanced-stage presentations, further intensifying demand for aggressive and multi-modal management strategies in specialized renal care units.

Market Segmentation

• By Treatment (Revenue, USD Bn, 2021-2033)
  • Drug Therapy
  • Hyperbaric Oxygen Therapy
• By End User (Revenue, USD Bn, 2021-2033)
  • Hospital and Clinics
  • Homecare
  • Ambulatory Centers
• By Region (Revenue, USD Bn, 2021-2033)
  • North America
    • U.S.
    • Canada
  • Latin America
    • Brazil
    • Mexico
    • Argentina
    • Rest of Latin America
  • Europe
    • Germany
    • U.K.
    • France
    • Italy
    • Spain
    • Russia
    • Rest of Europe
  • Asia Pacific
    • China
    • India
    • Japan
    • Australia
    • South Korea
    • ASEAN
    • Rest of Asia Pacific
  • Middle East
    • GCC
    • Israel
    • Rest of Middle East
  • Africa
    • South Africa
    • Central Africa
    • North Africa
• Key Players
  • 3M
  • Amgen Inc.
  • BSN Medical
  • ConvaTec Inc.
  • Medtronic Plc.
  • Smith & Nephew Plc.
  • Laboratoris Sanifit S.L.

Sources

Primary Research interviews

• Nephrologists and dermatologists involved in dialysis center care
• Hospital-based renal care specialists managing end-stage kidney disease patients
• Clinical researchers studying rare vascular calcification disorders
• Dialysis unit administrators and transplant coordinators

Databases

• PubMed clinical studies on calciphylaxis and vascular calcification
• NIH and National Library of Medicine databases
• ClinicalTrials.gov for ongoing and completed studies
• Global renal disease epidemiology datasets from WHO

Magazines

• Nephrology Times
• Kidney News
• Medical Tribune (renal care editions)
• Clinical Medicine Insight publications

Journals

• Journal of the American Society of Nephrology
• Kidney International
• Clinical Journal of the American Society of Nephrology
• Dermatology journals covering calciphylaxis case studies

Newspapers

• The New York Times (health section)
• The Guardian (health and science reporting)
• The Hindu (medical research coverage)
• Financial Times (healthcare innovation reporting)

Associations

• National Kidney Foundation
• International Society of Nephrology
• American Society of Nephrology
• European Renal Association

Public Domain sources

• World Health Organization (WHO) reports
• Centers for Disease Control and Prevention (CDC) publications
• Government health ministry reports on chronic kidney disease
• Open-access academic publications and conference abstracts

Proprietary Elements

• CMI Data Analytics Tool
• Proprietary CMI Existing Repository of information for last 10 years